Table 1 |
||
|
Characteristics of patients with rheumatoid arthritis in the two treatment groups |
||
|
Treatment |
||
|
|
||
|
Patients |
Infliximab |
Etanercept |
|
|
||
|
No. |
32 |
17 |
|
Age (years)a |
56.7 (23.5–80.9) |
55.3 (23.2–70.4) |
|
Female/male |
25/7 |
10/7 |
|
Duration of disease (years)a |
12.9 (3.0–55.5) |
13.7 (2.5–41.0) |
|
Serum CRP at baseline (mg/l)a |
20 (1–84) |
36 (1–85) |
|
Serum COMP at baseline (u/l)a |
11.3 (5.5–19.2) |
12.2 (8.1–29.7) |
|
DAS28 at baselinea |
5.3 (2.4–8.1) |
5.9 (3.7–7.5) |
|
HAQ at baselinea |
1.4 (0.4–2.8) |
1.6 (0.3–2.8) |
|
Monotherapy/combination therapy 5/27 |
3/14 |
|
|
Prednisolone/no prednisolone |
20/12 |
11/6 |
|
ACR20 response at 3 months |
16 (50%) |
11 (65%) |
|
|
||
|
There were no significant differences between the groups. aMedian (range). ACR20 = 20% improvement according to the American College of Rheumatology criteria; CRP = C-reactive protein; COMP = cartilage oligomeric matrix protein; DAS = disease activity score; HAQ = health assessment questionnaire. |
||
|
Crnkic et al. Arthritis Res Ther 2003 5:R181 doi:10.1186/ar760 |
||
